BCAX - Company ID 0002023658
The table below shows Bicara Therapeutics Inc.'s income statement line items across its last 3 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue | - | - | - |
| Cost of revenue | - | - | - |
| Gross profit | - | - | - |
| R&D | - | $63.60M | $30.60M |
| SG&A | $30.51M | $18.77M | $9.27M |
| Operating income | -$155.60M | -$82.39M | -$39.89M |
| Income tax | $217.00K | $187.00K | $5.00K |
| Net income |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| -$137.95M |
| -$68.00M |
| -$51.98M |
| EPS (diluted) | -$2.52 | -$4.05 | -$89.61 |